Skip to main content

25-09-2020 | EASD 2020 | Conference coverage | Article

DAPA-CKD trial: Renal benefits of SGLT2 inhibition in people with and without diabetes

DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes.

Read the transcript

Image Credits